Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc.

Madrigal (($MDGL)) has held its Q1 earnings call. Read on for the main highlights of the call. Madrigal’s latest earnings call struck a confident t...

Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of ...

Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $964.00. Accordi...

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

Madrigal (($MDGL)) has held its Q1 earnings call. Read on for the main highlights of the call. Madrigal’s latest earnings call struck an upbeat ton...

Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC), Madrigal Pharmaceuticals (MDGL) and Pulmonx (LUNG...

Analysts Conflicted on These Healthcare Names: Teladoc (TDOC), Madrigal Pharmaceuticals (MDGL) and Pulmonx (LUNG)

The latest announcement is out from Madrigal Pharmaceuticals ( ($MDGL) ). On April 22, 2026, Madrigal Pharmaceuticals’ board of directors reclassif...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$525.59	+1.61%	99.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$525.59	+1.6%	99.47K
3
4
5
6

MDGL

MDGL

No Data Available

Get Madrigal Pharmaceuticals Inc. Data in Excel

Get Madrigal Pharmaceuticals Inc. Data in Excel